New hope for kids with rare tumors: targeted drug enters safety trial

NCT ID NCT04928677

First seen Feb 22, 2026 · Last updated Apr 30, 2026 · Updated 9 times

Summary

This early-stage study tests a drug called codrituzumab in children and young adults (ages 1 to 21) whose solid tumors have come back or not responded to treatment and carry a specific protein called GPC3. The main goal is to find a safe dose and see how the body handles the drug. Up to 50 participants will be enrolled across multiple centers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY EXTRA-CRANIAL SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's Healthcare of Atlanta (Data Collection Only)

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Children's Hospital of Los Angeles (Data Collection Only)

    RECRUITING

    Los Angeles, California, 90027, United States

    Contact Phone: •••-•••-••••

  • Cincinnati Children's Hospital Medical Center

    RECRUITING

    Cincinnati, Ohio, 45229, United States

    Contact Phone: •••-•••-••••

  • Dana Farber Cancer Institute (Data Collection Only)

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-••••

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.